(±)-trans-GK563 is a selective inhibitor of Ca²⁺-independent phospholipase A₂ (GVIA iPLA₂) with an IC₅₀ of 1 nM; it exhibits 22,000-fold greater selectivity for GVIA iPLA₂ over GIVA cPLA₂; it reduces β-cell apoptosis induced by pro-inflammatory cytokines, suggesting its potential therapeutic application in autoimmune diseases such as type 1 diabetes.